RecruitingNot ApplicableNCT07209176

Physician- and Patient-based Barriers to NGS Testing

A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enrollment

256 participants

Start Date

Jan 6, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Prostate Cancer

Summary

The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study examines why men with metastatic prostate cancer are not getting next-generation genetic sequencing (NGS) testing — a type of genetic analysis that looks at the tumor's DNA to identify the best targeted therapy options. Both doctor-side and patient-side barriers will be explored to improve access to this important testing. **You may be eligible if...** - You are a man who has been diagnosed with metastatic prostate cancer (cancer that has spread beyond the prostate) - You are being seen as a new patient at Johns Hopkins Medical Oncology clinic - Your first visit falls between January 1, 2025 and December 31, 2026 **You may NOT be eligible if...** - You have already had NGS genetic testing performed on your cancer - You are not a new patient at the qualifying clinic - Your visit falls outside the study enrollment window This is an observational study — it collects information about your experience but does not change your treatment. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERProvider-level and patient education at end of study

The provider level component will involve an email to each of the genitourinary medical oncologists at Johns Hopkins with their NGS testing rate from preliminary data and compare this rate to the mean. The initial email will also include the 2025 ASCO guideline recommending somatic testing in virtually all metastatic prostate cancer patients. Providers who do not have baseline NGS testing rates available will also be emailed. Providers will subsequently be emailed their updated NGS testing rate at the conclusion of the study period. Patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing at the end of the study period.

OTHERProvider-level and patient-level

In addition to the provider component, patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing. The email will be sent by the MyChart Recruitment Innovation team. Those without email on file will have the same message and attachment sent via mail by our study coordinator.

Locations(1)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07209176

Related Trials

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT0580066525 locations

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

NCT0643922514 locations

A Study of Tarlatamab for People With Prostate Cancer

NCT0711150710 locations

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT0718116151 locations

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT0478774420 locations